Health Catalyst (HCAT) provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure. For the first quarter of 2025, we expect: Total revenue of approximately $79M, and Adjusted EBITDA of approximately $4M…
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- HCAT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Health Catalyst price target lowered to $8 from $12 at Piper Sandler
- Health Catalyst price target lowered to $10 from $11 at Canaccord
- Health Catalyst price target lowered to $7 from $9 at RBC Capital
- Health Catalyst to Acquire Upfront Healthcare Services